文献速递临床免疫质量管理与危急值

NOVEOS系统过敏原sIgE检测分析性能的双中心验证

Validation of the analytical performance of the NOVEOS™ System, a system which improves upon the third-generation in vitro allergy testing technology.
PubMed 文献 · Clin Chem Lab Med · 2020-01-01

该研究在德国两中心依据CLSI指南验证NOVEOS免疫分析仪检测过敏原特异性IgE的分析性能。结果显示重复性和室内精密度CV为3.0%-11.9%,空白限和检出限均<0.1 kU/L,所有过敏原线性良好,常见干扰物无显著干扰,与WHO参考标准一致性良好。

要点

  • NOVEOS系统检测sIgE的精密度CV为3.0%-11.9%,空白限和检出限均<0.1 kU/L。
  • 高浓度生物素、甲泼尼龙、苯海拉明、奥马珠单抗或雷尼替丁未显示显著干扰。
  • NOVEOS校准与最新WHO参考标准在两中心均显示良好一致性。

核心结论

  • NOVEOS系统在两中心的分析性能相当,精密度和线性良好,检出限<0.1 kU/L,常见干扰物影响极小,且校准至最新WHO参考标准。

研究设计与样本

  • 在德国马尔堡菲利普大学(Site-1)和柏林夏里特医学大学(Site-2)开展的双中心研究,依据CLSI指南I/LA20-A3、EP5-A3、EP17-A2、EP6-A、EP7-A3和EP9-A3评估NOVEOS系统的分析性能。

主要发现

  • 重复性和室内精密度测试在两中心均显示可接受性能,变异系数为3.0%-11.9%。
  • 两中心的空白限(LoB)和检出限(LoD)均<0.1 kU/L。
  • 所有测试过敏原在两中心均报告了参数内线性。
  • 高水平的生物素、甲泼尼龙、苯海拉明、奥马珠单抗或雷尼替丁未观察到显著干扰。
  • NOVEOS校准与最新WHO参考标准的方法学比较在两中心均显示良好一致性。

关键数值与推荐

  • 精密度变异系数为3.0%-11.9%(两中心重复性和室内精密度测试)。
  • 空白限和检出限均<0.1 kU/L(两中心)。
  • 所有测试过敏原在两中心均显示参数内线性。
  • 高浓度生物素、甲泼尼龙、苯海拉明、奥马珠单抗或雷尼替丁未观察到显著干扰。
  • NOVEOS校准与最新WHO参考标准在两中心均显示良好一致性。

临床怎么用

  • NOVEOS系统可用于过敏原sIgE的体外检测,其分析性能支持精密度、线性和检出限满足临床需求,且常见干扰物影响小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objectives Detection of allergen-specific immunoglobulin E (sIgE) is important for the diagnosis of allergy. IgE sensitization is commonly demonstrated in vivo by skin prick testing (SPT), or in vitro utilizing automated systems. Recently, HYCOR® Biomedical launched its new system for allergen sIgE testing called the NOVEOS™ Immunoanalyzer. This study aims to evaluate the analytical performance of the NOVEOS system in a bi-center study at Philipps-University Marburg (Site-1) and Charité Medical University Berlin (Site-2), respectively. Methods The analytical performance was evaluated based on the guidelines I/LA20-A3, EP5-A3, EP17-A2, EP6-A, EP7-A3, and EP9-A3 of the Clinical and Laboratory Standards Institute (CLSI). Results The conducted repeatability and within-laboratory precision tests provided acceptable performance with 3.0%-11.9% coefficient of variation across both sites. The limit of blank (LoB) and limit of detection (LoD) were <0.1 kU/L at both centers. A within-parameter linearity for all tested allergens was reported at both sites. Of note, no significant interference was observed for high levels of biotin, methylprednisolone, diphenhydramine, omalizumab, or ranitidine. Method comparison between the NOVEOS calibration and the latest World Health Organization (WHO) reference standard showed good agreement at both sites. Conclusions The results from the analytical performance of the NOVEOS allergen sIgE assay and instrument testing at both sites were comparable. Overall, a good precision and linearity as well as a detection limit <0.1 kU/L were observed, with minimal impact of common interfering substances on patient recoveries. The NOVEOS is calibrated to the latest WHO reference standard and adds benefits like a small sample size and para-magnetic microparticles that improve upon third-generation allergen sIgE assays' design and performance.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Bauersachs D, Potapova E, Renz H, et al. Validation of the analytical performance of the NOVEOS™ System, a system which improves upon the third-generation in vitro allergy testing technology. Clin Chem Lab Med. 2020. PMID: 32549134. doi:10.1515/cclm-2020-0535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。